Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

The 2019 annual conferences of the American Society of Clinical Oncology and the European Hematology Association befell, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16 June. At the conferences, outcomes from key research on the remedy of sufferers with relapsed or refractory multiple myeloma with high-risk cytogenetics had been introduced.

Our assembly report describes these research and contains interviews with investigators and commentaries by Canadian hematologists about the potential impression on Canadian observe.

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.
Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual conferences: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

DEX-2-TKA – DEXamethasone twice for ache remedy after Total Knee Arthroplasty. A protocol for a randomized, blinded, three-group multicentre scientific trial.

Multimodal analgesia is taken into account the main precept for postoperative ache remedy, however no gold customary after whole knee arthroplasty (TKA) exists.To examine the helpful and dangerous results of one or two doses of 24 mg intravenous dexamethasone as half of a multimodal analgesic routine (paracetamol, NSAID and perioperative native infiltration analgesia) after TKA.

We hypothesise that addition of dexamethasone will scale back postoperative opioid consumption.’DEXamethasone twice for ache remedy after TKA’ (DEX-2-TKA) is a randomized, blinded, three-group multicentre scientific trial. Participants might be randomized to at least one of three teams: placebo, single dose of dexamethasone, or two consecutive doses of dexamethasone.

Participants, remedy suppliers, and investigators might be blinded to the allotted intervention. The major end result is whole opioid consumption (items of morphine equivalents) 0-48 h postoperatively.unilateral, major TKA; age ≥18 years; AmericanSociety of Anesthesiologists (ASA)-Score 1-3; Body Mass Index ≥18 and ≤40; for ladies – not pregnant; and written knowledgeable consent.allergy or contraindications towards trial medicine; every day use of excessive dose opioid and/or use of methadone/transdermal opioids; every day use of systemic glucocorticoids; dysregulated diabetes; and sufferers struggling from alcohol and/or drug abuse.

Four-hundred-and-eighty-six eligible individuals are wanted to detect or discard a distinction of 10 mg morphine equivalents 0-48 h postoperatively sustaining a family-wise error price of 0.05 and a energy of 90% for the three potential pairwise comparisons.Recruiting is deliberate to start September 2018 and anticipated to complete March 2020.

Scroll to Top